We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I hope [this study] helps get rivaroxaban at this vascular dose used more often.”
“The finding of renal dysfunction should serve as a wake-up alarm for both clinicians and patients with chronic vascular disease; it alerts of an increased risk for adverse cardiovascular events, and this risk is modifiable.”
“The COMPASS trial showed that adding rivaroxaban vascular dose to low-dose aspirin significantly reduced vascular events. The large reduction in events [such as strokes], outweighed the increase in major bleeding events seen. Conducted in more than 30 countries, including the UK, COMPASS was one of the largest ever trials of oral anti-thrombotic therapy providing robust results, overall, and particularly for key patient subgroups at high-risk of recurrent events such as those with renal dysfunction or stable 'mild' heart failure.”
No takes yet. Share an insight, caveat, or question.
Fox et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: